Literature DB >> 10369113

Endothelin-1- and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease.

J Lutz1, M Gorenflo, M Habighorst, M Vogel, P E Lange, B Hocher.   

Abstract

Endothelin-1 (ET-1), with its vasoconstrictive and proliferation-stimulating effects, could play a role in the pathogenesis of primary pulmonary hypertension. We investigated the relationship between the ET-1 like immunoreactivity and the ET-receptor density, the grade of the pulmonary vasculopathy, and properties of the pulmonary circulation in patients with pulmonary hypertension due to congenital heart disease. Twenty-six patients with a median age of 1 year and 1 month (6 weeks - 17 years - 9 months) were assigned to group I (n = 15) with a pulmonary to systemic flow ratio (Qp/Qs) > or = 1.5 and a pulmonary to systemic resistance ratio (Rp/Rs) < or = 0.3 ("high flow - low resistance group") and to group II (n = 11) with a Qp/Qs < 1.5 and an Rp/Rs > 0.3 ("low flow - high resistance group"). Patients belonging to group II showed a higher ET(A)-receptor density in lung arteries (p < 0.05) and parenchyma (p < 0.01) than patients in group I. Patients with the highest ET-1 like immunoreactivity in lung artery walls also showed a trend towards a higher ET(A)-receptor density. The ET(B)-receptor expression was low and not related to any of the above factors. Our results suggest that the paracrine lung ET-1 system is up-regulated in pediatric patients with secondary pulmonary hypertension associated with congenital heart disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369113     DOI: 10.1515/CCLM.1999.069

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

Review 1.  Pulmonary arterial hypertension: new ideas and perspectives.

Authors:  N Galiè; A Torbicki
Journal:  Heart       Date:  2001-04       Impact factor: 5.994

Review 2.  Pulmonary arterial hypertension: a comparison between children and adults.

Authors:  R J Barst; S I Ertel; M Beghetti; D D Ivy
Journal:  Eur Respir J       Date:  2011-03       Impact factor: 16.671

Review 3.  Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease.

Authors:  Markus P Schneider; Erika I Boesen; David M Pollock
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

4.  Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in the rat.

Authors:  Martina Wendel; Anna Petzold; Roland Koslowski; Michael Kasper; Antje Augstein; Lilla Knels; Jörg-Uwe Bleyl; Thea Koch
Journal:  Histochem Cell Biol       Date:  2004-10-05       Impact factor: 4.304

5.  Argon reduces the pulmonary vascular tone in rats and humans by GABA-receptor activation.

Authors:  Said Suleiman; Sergej Klassen; Ira Katz; Galina Balakirski; Julia Krabbe; Saskia von Stillfried; Svetlana Kintsler; Till Braunschweig; Aaron Babendreyer; Jan Spillner; Sebastian Kalverkamp; Thomas Schröder; Manfred Moeller; Mark Coburn; Stefan Uhlig; Christian Martin; Annette D Rieg
Journal:  Sci Rep       Date:  2019-02-13       Impact factor: 4.379

6.  Bosentan for increased pulmonary vascular resistance in a patient with single ventricle physiology and a bidirectional Glenn shunt.

Authors:  J K Votava-Smith; G S Perens; J C Alejos
Journal:  Pediatr Cardiol       Date:  2007-06-11       Impact factor: 1.838

7.  Rosiglitazone Attenuated Endothelin-1-Induced Vasoconstriction of Pulmonary Arteries in the Rat Model of Pulmonary Arterial Hypertension via Differential Regulation of ET-1 Receptors.

Authors:  Yahan Liu; Xiao Yu Tian; Yu Huang; Nanping Wang
Journal:  PPAR Res       Date:  2014-02-18       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.